nelivaptan

chemical compound

Uses your system voice; voice and rate in settings.

Q6989992Snapshot

≈ 1 min read

Names in other languages

  • Englishnelivaptan
  • فارسینلی‌واپتان
  • shNelivaptan
  • СрпскиNelivaptan
  • Tiếng ViệtNelivaptan

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Nelivaptan ( ; developmental code names SSR-149415, NB-415, and BH-200) is a selective, orally active, non-peptide vasopressin V 1B receptor antagonist. The drug had entered clinical trials for treatment of anxiety and depression. In July 2008, Sanofi-Aventis announced that further development of this drug had been halted.

Subsequently, nelivaptan was developed by Nelivabon for treatment of depressive disorders under the code name NB-145, but development was discontinued in 2022. However, it is also under development by HMNC Brain Health for major depressive disorder under the code name BH-200, and is in phase 2 trials for this indication as of August 2025.

See also

Vasopressin receptor antagonist List of investigational antidepressants List of investigational anxiolytics ABT-436 Balovaptan SRX-246 TS-121

Text derived from https://en.wikipedia.org/w/index.php?oldid=1372024667 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.